Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Autoimmune Syndromes Presenting as a Paraneoplastic Manifestation of Myelodysplastic Syndromes: Clinical Features, Course, Treatment and Outcome.

Williamson BT, Foltz L, Leitch HA.

Hematol Rep. 2016 May 10;8(2):6480. doi: 10.4081/hr.2016.6480. eCollection 2016 May 10.

2.

Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy.

Enright H, Jacob HS, Vercellotti G, Howe R, Belzer M, Miller W.

Br J Haematol. 1995 Oct;91(2):403-8.

PMID:
8547082
3.

Inflammatory arthritis in patients with myelodysplastic syndromes: a multicenter retrospective study and literature review of 68 cases.

Mekinian A, Braun T, Decaux O, Falgarone G, Toussirot E, Raffray L, Omouri M, Gombert B, De Wazieres B, Buchdaul AL, Ziza JM, Launay D, Denis G, Madaule S, Rose C, Grignano E, Fenaux P, Fain O; Club Rhumatismes et Inflammation (CRI), Groupe Francophone des Myélodysplasies (GFM); Société Nationale Française de Médecine Interne (SNFMI).

Medicine (Baltimore). 2014 Jan;93(1):1-10. doi: 10.1097/MD.0000000000000011. Review.

4.

Autoimmune phenomena in patients with myelodysplastic syndromes.

Enright H, Miller W.

Leuk Lymphoma. 1997 Feb;24(5-6):483-9. Review.

PMID:
9086438
5.

Paraneoplastic inflammation in myelodysplastic syndrome or bone marrow failure: case series with focus on 5-azacytidine and literature review.

Frietsch JJ, Dornaus S, Neumann T, Scholl S, Schmidt V, Kunert C, Sayer HG, Hochhaus A, La Rosée P.

Eur J Haematol. 2014 Sep;93(3):247-59. doi: 10.1111/ejh.12311. Epub 2014 Apr 9. Review.

PMID:
24635656
6.

Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study.

Mekinian A, Grignano E, Braun T, Decaux O, Liozon E, Costedoat-Chalumeau N, Kahn JE, Hamidou M, Park S, Puéchal X, Toussirot E, Falgarone G, Launay D, Morel N, Trouiller S, Mathian A, Gombert B, Schoindre Y, Lioger B, De Wazieres B, Amoura Z, Buchdaul AL, Georgin-Lavialle S, Dion J, Madaule S, Raffray L, Cathebras P, Piette JC, Rose C, Ziza JM, Lortholary O, Montestruc F, Omouri M, Denis G, Rossignol J, Nimubona S, Adès L, Gardin C, Fenaux P, Fain O.

Rheumatology (Oxford). 2016 Feb;55(2):291-300. doi: 10.1093/rheumatology/kev294. Epub 2015 Sep 8.

PMID:
26350487
7.

Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.

Saif MW, Hopkins JL, Gore SD.

Leuk Lymphoma. 2002 Nov;43(11):2083-92. Review.

PMID:
12533032
8.

Inflammatory disorders associated with trisomy 8-myelodysplastic syndromes: French retrospective case-control study.

Wesner N, Drevon L, Guedon A, Fraison JB, Trad S, Kahn JE, Aouba A, Gillard J, Ponsoye M, Hanslik T, Gourguechon C, Liozon E, Laribi K, Rossignol J, Hermine O, Adès L, Carrat F, Fenaux P, Mekinian A, Fain O; On behalf GFM, MINHEMON (French Network of Dysimmune Disorders Associated to Hemopathies).

Eur J Haematol. 2018 Sep 15. doi: 10.1111/ejh.13174. [Epub ahead of print]

PMID:
30218579
9.

Rheumatic manifestations of the myelodysplastic syndromes: a comparative study.

Chandran G, Ahern MJ, Seshadri P, Coghlan D.

Aust N Z J Med. 1996 Oct;26(5):683-8.

PMID:
8958365
10.

[Systemic and autoimmune manifestations in myelodysplastic syndromes].

Fain O, Braun T, Stirnemann J, Fenaux P.

Rev Med Interne. 2011 Sep;32(9):552-9. doi: 10.1016/j.revmed.2010.08.005. Epub 2010 Sep 20. French.

PMID:
20850913
11.

Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group.

Götze K, Platzbecker U, Giagounidis A, Haase D, Lübbert M, Aul C, Ganser A, Germing U, Hofmann WK.

Ann Hematol. 2010 Sep;89(9):841-50. doi: 10.1007/s00277-010-1015-0. Epub 2010 Jun 22. Review.

PMID:
20567826
12.

Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program.

Musto P, Maurillo L, Spagnoli A, Gozzini A, Rivellini F, Lunghi M, Villani O, Aloe-Spiriti MA, Venditti A, Santini V; Ad Hoc Italian Cooperative Study Group on Azacitidine in Myelodysplastic Syndromes Acute Leukemias.

Cancer. 2010 Mar 15;116(6):1485-94. doi: 10.1002/cncr.24894.

13.

Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS.

Zeidan AM, Lee JW, Prebet T, Greenberg P, Sun Z, Juckett M, Smith MR, Paietta E, Gabrilove J, Erba HP, Katterling RP, Tallman MS, Gore SD.

Br J Haematol. 2014 Oct;167(1):62-8. doi: 10.1111/bjh.13008. Epub 2014 Jul 4.

14.

Remission of relapsing polychondritis after successful treatment of myelodysplastic syndrome with azacitidine: a case and review of the literature.

Erden A, Bilgin E, Kılıç L, Sarı A, Armağan B, Büyükaşık Y, Kalyoncu U.

Drug Metab Pers Ther. 2018 Jun 27;33(2):105-108. doi: 10.1515/dmpt-2018-0002.

PMID:
29715182
15.

New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.

Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, Granada I, Hildebrandt B, Slovak ML, Ohyashiki K, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Valent P, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Garcia-Manero G, Faderl S, Pierce S, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D.

J Clin Oncol. 2012 Mar 10;30(8):820-9. doi: 10.1200/JCO.2011.35.6394. Epub 2012 Feb 13.

16.

Antiretroviral activity of 5-azacytidine during treatment of a HTLV-1 positive myelodysplastic syndrome with autoimmune manifestations.

Diamantopoulos PT, Michael M, Benopoulou O, Bazanis E, Tzeletas G, Meletis J, Vayopoulos G, Viniou NA.

Virol J. 2012 Jan 3;9:1. doi: 10.1186/1743-422X-9-1.

17.

Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications.

Pleyer L, Burgstaller S, Stauder R, Girschikofsky M, Sill H, Schlick K, Thaler J, Halter B, Machherndl-Spandl S, Zebisch A, Pichler A, Pfeilstöcker M, Autzinger EM, Lang A, Geissler K, Voskova D, Geissler D, Sperr WR, Hojas S, Rogulj IM, Andel J, Greil R.

J Hematol Oncol. 2016 Apr 16;9:39. doi: 10.1186/s13045-016-0263-4.

18.

Behçet's disease associated with myelodysplastic syndromes. A case report and a review of the literature.

Ohno E, Ohtsuka E, Watanabe K, Kohno T, Takeoka K, Saburi Y, Kikuchi H, Nasu M.

Cancer. 1997 Jan 15;79(2):262-8. Review.

PMID:
9010099
19.

Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations.

Kim YJ, Jang JH, Kwak JY, Lee JH, Kim HJ.

Blood Res. 2013 Jun;48(2):87-98. doi: 10.5045/br.2013.48.2.87. Epub 2013 Jun 25.

20.

[Systemic diseases in myelodysplastic syndromes].

Hebbar M, Hebbar-Savéan K, Fenaux P.

Rev Med Interne. 1995;16(12):897-904. Review. French.

PMID:
8570952

Supplemental Content

Support Center